BNCT Triggers Immunogenic Cell Death in B16 Melanoma Without Accompanying T-Cell Infiltration--Implications for Combination Immunotherapy
Objective: Boron neutron capture therapy (BNCT) is a targeted radiotherapy with highly selective tumor killing; its potential to induce immunogenic cell death (ICD) and modulate the tumor immune microenvironment has attracted attention. However, whether BNCT-induced immune activation can overcome the T-cell exclusion barrier of immunologically "cold" tumors and translate into intratumoral…
A study investigates the effects of boron neutron capture therapy (BNCT) on B16 melanoma in mice, focusing on whether it can trigger immunogenic cell death (ICD) and cause intratumoral effector T-cell infiltration. The research compares various treatment regimens, including neutron irradiation alone, BNCT alone, and BNCT combined with a specific drug dose.
On day 7, results show that while BNCT significantly reduces tumor growth, it does not lead to T-cell infiltration in the tumor microenvironment, unlike neutron irradiation. The study highlights the potential of BNCT to induce ICD and modulate the tumor immune microenvironment, suggesting its role in combination immunotherapy.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
